Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Initiation
SVB Leerink bearish on Arrowhead, initiates with an Underperform » 09:04
01/21/20
01/21
09:04
01/21/20
09:04
ARWR

Arrowhead

$56.42 /

-0.65 (-1.14%)

, VRTX

Vertex

$235.85 /

+0.23 (+0.10%)

, JNJ

Johnson & Johnson

$149.07 /

+0.82 (+0.55%)

As previously reported,…

As previously reported, SVB Leerink analyst Mani Foroohar initiated coverage of Arrowhead (ARWR) with an Underperform rating and $32 price target. The analyst notes that safety profile and regulatory path for lead asset ARO-AAT remains uncertain, and competitor data from Vertex (VRTX) is an existential threat to the program. Non-dilutive financing and potential royalties from the Johnson & Johnson (JNJ) partnership are more than fully valued at current levels, he adds. With a tough catalyst path and current valuation baking in substantial technology value despite very few patient-years of exposure to the TRiM platform, Foroohar sees the next 12 months as far more challenging than the past two years as Arrowhead faces sky-high expectations in the face of increasingly clear competitive headwinds.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Cantor Fitzgerald healthcare analyst to hold analyst/industry conference call » 08:48
01/21/20
01/21
08:48
01/21/20
08:48
VRTX

Vertex

$235.85 /

+0.23 (+0.10%)

, BMRN

BioMarin

$88.27 /

-0.82 (-0.92%)

, ALNY

Alnylam

$118.77 /

-0.54 (-0.45%)

, ACAD

Acadia

$43.42 /

-1.17 (-2.62%)

, TGTX

TG Therapeutics

$13.71 /

-0.32 (-2.28%)

, BHVN

Biohaven Pharmaceutical

$55.99 /

+4.27 (+8.26%)

, ARVN

Arvinas

$50.96 /

-0.29 (-0.57%)

, IMMU

Immunomedics

$19.01 /

-0.3 (-1.55%)

, MRNS

Marinus Pharmaceuticals

$2.26 /

-0.04 (-1.74%)

, CARA

Cara Therapeutics

$17.30 /

+0.42 (+2.49%)

, KDMN

Kadmon

$4.54 /

+0.245 (+5.71%)

, MGNX

MacroGenics

$11.27 /

-0.34 (-2.93%)

, MBIO

Mustang Bio

$4.33 /

-0.19 (-4.20%)

Healthcare Analyst Young…

Healthcare Analyst Young discusses the industry's outlook for 2020 and Top Picks for Large Cap Biotech, VRTX and BMRN; Mid-Cap Biotech, ALNY & ACAD, Small-Cap Biotech TGTX, BHVN, ARVN & IMMU; Micro-Cap Biotech, MRNS, CARA, KDMN, MGNX & MBIO on an Analyst/Industry conference call to be held on January 21 at 10 am.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Thursday
Conference/Events
JPMorgan to hold a conference » 04:55
01/16/20
01/16
04:55
01/16/20
04:55
AGIO

Agios Pharmaceuticals

$50.20 /

+0.96 (+1.95%)

, ASND

Ascendis Pharma

$138.87 /

+0.04 (+0.03%)

, TDOC

Teladoc

$93.94 /

-2.935 (-3.03%)

, GILD

Gilead

$64.11 /

-0.11 (-0.17%)

, NVCR

Novocure

$84.37 /

+1.96 (+2.38%)

, JAZZ

Jazz Pharmaceuticals

$152.80 /

+2.79 (+1.86%)

, TEVA

Teva

$10.56 /

+0.51 (+5.07%)

, PGNY

Progyny

$31.02 /

-2.315 (-6.95%)

, VRTX

Vertex

$234.03 /

+4.24 (+1.85%)

, HCAT

Health Catalyst

$36.14 /

+0.78 (+2.21%)

, UTHR

United Therapeutics

$92.46 /

+0.67 (+0.73%)

, JNJ

Johnson & Johnson

$146.97 /

+0.39 (+0.27%)

, WELL

Welltower

$84.99 /

+0.96 (+1.14%)

, VIR

Vir Biotechnology

$15.28 /

+0.77 (+5.31%)

, TFX

Teleflex

$380.15 /

-2.975 (-0.78%)

, RGEN

Repligen

$99.66 /

+0.2 (+0.20%)

, REPL

Replimune Group

$18.27 /

+0.29 (+1.61%)

, RIGL

Rigel Pharmaceuticals

$2.73 /

+0.115 (+4.40%)

, NVRO

Nevro

$118.14 /

+3.805 (+3.33%)

, OYST

Oyster Point Pharma

$25.56 /

-1.25 (-4.66%)

, NVO

Novo Nordisk

$62.39 /

+2.77 (+4.65%)

, MYOK

MyoKardia

$75.97 /

-0.78 (-1.02%)

, MOH

Molina Healthcare

$139.00 /

+7.15 (+5.42%)

, LH

LabCorp

$178.20 /

-2.13 (-1.18%)

, LLY

Eli Lilly

$141.09 /

+0.45 (+0.32%)

, LMNX

Luminex

$23.49 /

-0.1 (-0.42%)

, ILMN

Illumina

$320.48 /

+3.38 (+1.07%)

, ITCI

Intra-Cellular

$26.31 /

-0.49 (-1.83%)

, HOLX

Hologic

$53.75 /

+0.26 (+0.49%)

, IDYA

Ideaya Biosciences

$10.96 /

+0.52 (+4.98%)

, FOLD

Amicus

$10.40 /

+0.54 (+5.48%)

, EBS

Emergent BioSolutions

$54.92 /

-0.11 (-0.20%)

, CTLT

Catalent

$60.85 /

+0.51 (+0.85%)

38th Annual Healthcare…

38th Annual Healthcare Conference will be held in San Francisco on January 13-16.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Over a week ago
Conference/Events
JPMorgan to hold a conference » 04:55
01/15/20
01/15
04:55
01/15/20
04:55
AGIO

Agios Pharmaceuticals

$49.24 /

+3.92 (+8.65%)

, ASND

Ascendis Pharma

$138.83 /

+0.75 (+0.54%)

, TDOC

Teladoc

$96.88 /

+1.025 (+1.07%)

, GILD

Gilead

$64.22 /

-0.08 (-0.12%)

, NVCR

Novocure

$82.41 /

+1.27 (+1.57%)

, JAZZ

Jazz Pharmaceuticals

$150.01 /

+4.07 (+2.79%)

, TEVA

Teva

$10.05 /

+0.87 (+9.48%)

, PGNY

Progyny

$33.33 /

+1.53 (+4.81%)

, VRTX

Vertex

$229.79 /

+3.33 (+1.47%)

, HCAT

Health Catalyst

$35.36 /

-2.3 (-6.11%)

, UTHR

United Therapeutics

$91.79 /

+5.56 (+6.45%)

, JNJ

Johnson & Johnson

$146.58 /

+0.87 (+0.60%)

, WELL

Welltower

$84.03 /

-0.03 (-0.04%)

, VIR

Vir Biotechnology

$14.51 /

+1.29 (+9.76%)

, TFX

Teleflex

$383.13 /

+4.565 (+1.21%)

, RGEN

Repligen

$99.46 /

+0.45 (+0.45%)

, REPL

Replimune Group

$17.98 /

+0.12 (+0.67%)

, RIGL

Rigel Pharmaceuticals

$2.62 /

+0.445 (+20.51%)

, NVRO

Nevro

$114.34 /

-1.65 (-1.42%)

, OYST

Oyster Point Pharma

$26.81 /

-1.15 (-4.11%)

, NVO

Novo Nordisk

$59.62 /

+0.66 (+1.12%)

, MYOK

MyoKardia

$76.75 /

+4.35 (+6.01%)

, MOH

Molina Healthcare

$131.79 /

-7.99 (-5.72%)

, LH

LabCorp

$180.33 /

+1.26 (+0.70%)

, LLY

Eli Lilly

$140.64 /

+1.67 (+1.20%)

, LMNX

Luminex

$23.59 /

+0.31 (+1.33%)

, ILMN

Illumina

$317.10 /

-5.5 (-1.70%)

, ITCI

Intra-Cellular

$26.80 /

+0.07 (+0.26%)

, HOLX

Hologic

$53.49 /

+0.58 (+1.10%)

, IDYA

Ideaya Biosciences

$10.44 /

+0.17 (+1.66%)

, FOLD

Amicus

$9.86 /

+0.93 (+10.41%)

, EBS

Emergent BioSolutions

$55.03 /

+0.435 (+0.80%)

, CTLT

Catalent

$60.34 /

+0.88 (+1.48%)

38th Annual Healthcare…

38th Annual Healthcare Conference will be held in San Francisco on January 13-16.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
JPMorgan to hold a conference » 04:55
01/14/20
01/14
04:55
01/14/20
04:55
AGIO

Agios Pharmaceuticals

$45.32 /

-2.97 (-6.15%)

, ASND

Ascendis Pharma

$138.08 /

+0.9 (+0.66%)

, TDOC

Teladoc

$95.85 /

+10.71 (+12.58%)

, GILD

Gilead

$64.30 /

-0.72 (-1.11%)

, NVCR

Novocure

$81.14 /

-3.23 (-3.83%)

, JAZZ

Jazz Pharmaceuticals

$145.94 /

-0.88 (-0.60%)

, TEVA

Teva

$9.18 /

+0.17 (+1.89%)

, PGNY

Progyny

$31.80 /

+2.46 (+8.38%)

, VRTX

Vertex

$226.46 /

-2.46 (-1.07%)

, HCAT

Health Catalyst

$37.66 /

+0.85 (+2.31%)

, UTHR

United Therapeutics

$86.23 /

+0.63 (+0.74%)

, JNJ

Johnson & Johnson

$145.71 /

+0.63 (+0.43%)

, WELL

Welltower

$84.06 /

+1.24 (+1.50%)

, VIR

Vir Biotechnology

$13.22 /

+0.36 (+2.80%)

, TFX

Teleflex

$378.56 /

-0.095 (-0.03%)

, RGEN

Repligen

$99.01 /

+1.07 (+1.09%)

, REPL

Replimune Group

$17.86 /

+0.08 (+0.45%)

, RIGL

Rigel Pharmaceuticals

$2.17 /

+0.085 (+4.08%)

, NVRO

Nevro

$115.99 /

-1.535 (-1.31%)

, OYST

Oyster Point Pharma

$27.96 /

+1.29 (+4.84%)

, NVO

Novo Nordisk

$58.96 /

+0.27 (+0.46%)

, MYOK

MyoKardia

$72.40 /

+0.79 (+1.10%)

, MOH

Molina Healthcare

$139.78 /

-3.69 (-2.57%)

, LH

LabCorp

$179.07 /

+1.56 (+0.88%)

, LLY

Eli Lilly

$138.97 /

+0.96 (+0.70%)

, LMNX

Luminex

$23.28 /

+0.14 (+0.61%)

, ILMN

Illumina

$322.60 /

-12.83 (-3.82%)

, ITCI

Intra-Cellular

$26.73 /

+0.825 (+3.18%)

, HOLX

Hologic

$52.91 /

-0.27 (-0.51%)

, IDYA

Ideaya Biosciences

$10.27 /

+1.27 (+14.11%)

, FOLD

Amicus

$8.93 /

-0.5 (-5.30%)

, EBS

Emergent BioSolutions

$54.60 /

-1.095 (-1.97%)

, CTLT

Catalent

$59.46 /

+1.77 (+3.07%)

38th Annual Healthcare…

38th Annual Healthcare Conference will be held in San Francisco on January 13-16.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
JPMorgan to hold a conference » 08:35
01/13/20
01/13
08:35
01/13/20
08:35
AGIO

Agios Pharmaceuticals

$48.29 /

-0.25 (-0.52%)

, ASND

Ascendis Pharma

$137.18 /

-1.97 (-1.42%)

, TDOC

Teladoc

$85.14 /

-0.18 (-0.21%)

, GILD

Gilead

$65.02 /

-0.83 (-1.26%)

, NVCR

Novocure

$84.37 /

+3.4 (+4.20%)

, JAZZ

Jazz Pharmaceuticals

$146.82 /

+1.29 (+0.89%)

, TEVA

Teva

$9.01 /

-0.01 (-0.11%)

, PGNY

Progyny

$29.34 /

+0.64 (+2.23%)

, VRTX

Vertex

$228.92 /

-1.23 (-0.53%)

, HCAT

Health Catalyst

$36.81 /

-0.42 (-1.13%)

, UTHR

United Therapeutics

$85.60 /

-1.98 (-2.26%)

, JNJ

Johnson & Johnson

$145.08 /

-0.33 (-0.23%)

, WELL

Welltower

$82.82 /

+0.35 (+0.42%)

, VIR

Vir Biotechnology

$12.86 /

+0.275 (+2.19%)

, TFX

Teleflex

$378.66 /

-0.6 (-0.16%)

, RGEN

Repligen

$97.94 /

+1.56 (+1.62%)

, REPL

Replimune Group

$17.78 /

+1.28 (+7.76%)

, RIGL

Rigel Pharmaceuticals

$2.09 /

-0.07 (-3.25%)

, NVRO

Nevro

$117.52 /

+ (+0.00%)

, OYST

Oyster Point Pharma

$26.67 /

-0.14 (-0.52%)

, NVO

Novo Nordisk

$58.69 /

+1.25 (+2.18%)

, MYOK

MyoKardia

$71.61 /

+1.75 (+2.51%)

, MOH

Molina Healthcare

$143.47 /

+0.035 (+0.02%)

, LH

LabCorp

$177.51 /

+2.52 (+1.44%)

, LLY

Eli Lilly

$138.01 /

+2.08 (+1.53%)

, LMNX

Luminex

$23.14 /

+0.05 (+0.22%)

, ILMN

Illumina

$335.43 /

+0.9 (+0.27%)

, ITCI

Intra-Cellular

$25.91 /

+0.485 (+1.91%)

, HOLX

Hologic

$53.18 /

-0.12 (-0.23%)

, IDYA

Ideaya Biosciences

$9.00 /

+0.52 (+6.13%)

, FOLD

Amicus

$9.43 /

-0.23 (-2.38%)

, EBS

Emergent BioSolutions

$55.69 /

-0.82 (-1.45%)

, CTLT

Catalent

$57.69 /

+0.73 (+1.28%)

38th Annual Healthcare…

38th Annual Healthcare Conference will be held in San Francisco on January 13-16.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Vertex price target raised to $268 from $248 at BMO Capital » 07:22
01/09/20
01/09
07:22
01/09/20
07:22
VRTX

Vertex

$231.14 /

+7.26 (+3.24%)

BMO Capital analyst Do…

BMO Capital analyst Do Kim raised his price target for Vertex to $268 from $248, as estimates increase to reflect broader ex-U.S. reimbursement coverage and greater ex-U.S. uptake across all CF mutations with expected Trikafta approval. The analyst expects shares to be driven by the pace of Trikafta adoption and growth trajectory of the total CF franchise to consensus peak sales of $9.4B.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Molecular Templates expects collaborations to advance in 2020 » 09:02
01/08/20
01/08
09:02
01/08/20
09:02
MTEM

Molecular Templates

$13.52 /

+0.4 (+3.05%)

, VRTX

Vertex

$223.88 /

-0.18 (-0.08%)

, TAK

Takeda Pharmaceutical

$19.60 /

-0.19 (-0.96%)

On November 18, 2019,…

On November 18, 2019, MTEM (MTEM) and Vertex Pharmaceuticals (VRTX) announced a strategic research collaboration to discover and develop novel targeted conditioning regimens that may enhance the hematopoietic stem cell transplant process, including transplants conducted as part of treatment with ex vivo CRISPR/Cas9 gene editing therapies such as CTX001. Under the collaboration, MTEM will conduct research activities for the use of ETBs for up to two targets selected by Vertex. The initial research will be focused on discovering a novel conditioning regimen using MTEM's ETB technology platform. In addition, Vertex has an option to select a second target as part of the collaboration. Vertex made an up-front payment of $38M to MTEM, including an equity investment. MTEM is also eligible to receive future development, regulatory and sales milestones and option payments of up to $522M and tiered royalty payments on future sales. On November 21, 2019, MTEM announced the pricing of an underwritten equity offering, the net proceeds of which were approximately $53.3M, after deducting underwriting discounts and commissions and other estimated offering expenses payable by MTEM. MTEM has three ongoing collaborations: the co-development collaboration with Takeda (TAK) for TAK-169, the multi-target collaboration with Takeda for the discovery and development of new ETBs against two undisclosed oncology targets, and the multi-target collaboration with Vertex for the discovery and development of new conditioning regimens. All three of these collaborations are expected to advance in 2020.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Vertex price target raised to $265 from $230 at Oppenheimer » 07:53
01/08/20
01/08
07:53
01/08/20
07:53
VRTX

Vertex

$223.88 /

-0.18 (-0.08%)

Oppenheimer analyst…

Oppenheimer analyst Hartaj Singh raised his price target for Vertex to $265 from $230, while reiterating an Outperform rating on the shares. While the Street expects the Trikafta launch to be strong, the analyst believes a stronger than expected launch is not priced in and some early/mid-stage clinical readouts in 2020 could provide another lift.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Citi ups Vertex price trarget to $265, calls a top pick for 2020 » 06:51
01/08/20
01/08
06:51
01/08/20
06:51
VRTX

Vertex

$223.88 /

-0.18 (-0.08%)

Citi analyst Mohit Bansal…

Citi analyst Mohit Bansal raised his price target for Vertex Pharmaceuticals to $265 and calls the stock a top pick for 2020. The analyst thinks the shares remain undervalued. The company is expected to grow sales at over 20% and earnings at over 30% through 2022, Bansal tells investors in a research note. In addition, the analyst sees $500M-$650M upside to consensus cystic fibrosis numbers in the 2022-2025 time-frame as he thinks Trikafta conversion could be rapid once the initial bottle-neck is resolved. Further, Bansal believes Vertex's alpha-1 antitrypsin deficiency program is differentiated with a reasonable likelihood of success. He sees this as a $3B peak opportunity for the company.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.